Equities

Profile data is unavailable for this security.

About the company

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

  • Revenue in USD (TTM)81.33bn
  • Net income in USD16.33bn
  • Incorporated1887
  • Employees135.10k
  • Location
    Johnson & Johnson1 Johnson And Johnson PlzNEW BRUNSWICK 08933-0001United StatesUSA
  • Phone+1 (732) 524-2455
  • Fax+1 (732) 214-0332
  • Websitehttps://www.jnj.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
JNJ:NYQ since
announced
Transaction
value
Innovalens BVDeal completed15 Feb 201915 Feb 2019Deal completed-1.67%--
CIC CorpDeal completed23 Oct 201823 Oct 2018Deal completed-4.77%711.33m
Ci:z Holdings Co LtdDeal completed23 Oct 201823 Oct 2018Deal completed-4.77%1.33bn
EIT Emerging Implant Technologies GmbHAnnounced31 Aug 201831 Aug 2018Announced-2.13%--
Data delayed at least 15 minutes, as of Jul 18 2019 21:00 BST.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.